Exclusive: SunTrust Top Analysts Explain Fatty Liver Diseases, Galmed's Potential In The Space
October 18, 2016 at 13:32 PM EDT
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has had a bad year, with its stock down more than 49 percent. However, analysts have noted the ...
